| pubmed-article:489967 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:489967 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:489967 | lifeskim:mentions | umls-concept:C0033477 | lld:lifeskim |
| pubmed-article:489967 | lifeskim:mentions | umls-concept:C0021083 | lld:lifeskim |
| pubmed-article:489967 | lifeskim:mentions | umls-concept:C0442034 | lld:lifeskim |
| pubmed-article:489967 | lifeskim:mentions | umls-concept:C0029925 | lld:lifeskim |
| pubmed-article:489967 | lifeskim:mentions | umls-concept:C0596402 | lld:lifeskim |
| pubmed-article:489967 | lifeskim:mentions | umls-concept:C0205369 | lld:lifeskim |
| pubmed-article:489967 | lifeskim:mentions | umls-concept:C0086597 | lld:lifeskim |
| pubmed-article:489967 | lifeskim:mentions | umls-concept:C1879547 | lld:lifeskim |
| pubmed-article:489967 | lifeskim:mentions | umls-concept:C0591833 | lld:lifeskim |
| pubmed-article:489967 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:489967 | pubmed:dateCreated | 1979-12-29 | lld:pubmed |
| pubmed-article:489967 | pubmed:abstractText | Immunotherapy with a combination of Corynebacterium parvum and specific heteroantiserum is significantly more effective than treatment with either single agent in prolonging the survival of mice that have recevied an i.p. injection of syngeneic murine ovarian carcinoma (MOT) cells. Invitro, a combination of C. parvum-activated peritoneal cells and specific heteroantiserum has proven significantly more effective than either single component in destroying 51Cr-labeled MOT cells in the absence of complement. Activation of peritoneal cells to produce lysis of tumor in the presence specific antiserum peaked 3 to 7 days after a single injection of C. parvum and declined to baseline over 3 to 4 weeks. With repeated i.p. injections of C. parvum at appropriate intervals, activation of peritoneal cells could be prolonged and augmented. Among the routes tested, only i.p. administration of C. parvum was effective, although activation of peritoneal cells for cooperation with heteroantiserum was observed over a broad range of i.p. dosage (0.45 to 4.20 mg). These data suggest that the administration of C. parvum by appropriate doses, routes, and schedules can attract and activate a population of peritoneal effectors that mediate antibody-dependent cytotoxicity more effectively than resident peritoneal cells. | lld:pubmed |
| pubmed-article:489967 | pubmed:language | eng | lld:pubmed |
| pubmed-article:489967 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:489967 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:489967 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:489967 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:489967 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:489967 | pubmed:issn | 0022-1767 | lld:pubmed |
| pubmed-article:489967 | pubmed:author | pubmed-author:SchlossmanS... | lld:pubmed |
| pubmed-article:489967 | pubmed:author | pubmed-author:KnappR CRC | lld:pubmed |
| pubmed-article:489967 | pubmed:author | pubmed-author:TuckerR WRW | lld:pubmed |
| pubmed-article:489967 | pubmed:author | pubmed-author:BartT HTH | lld:pubmed |
| pubmed-article:489967 | pubmed:author | pubmed-author:ThurstonJ GJG | lld:pubmed |
| pubmed-article:489967 | pubmed:author | pubmed-author:MitchellA KAK | lld:pubmed |
| pubmed-article:489967 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:489967 | pubmed:volume | 123 | lld:pubmed |
| pubmed-article:489967 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:489967 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:489967 | pubmed:pagination | 1945-51 | lld:pubmed |
| pubmed-article:489967 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:489967 | pubmed:meshHeading | pubmed-meshheading:489967-A... | lld:pubmed |
| pubmed-article:489967 | pubmed:meshHeading | pubmed-meshheading:489967-M... | lld:pubmed |
| pubmed-article:489967 | pubmed:meshHeading | pubmed-meshheading:489967-I... | lld:pubmed |
| pubmed-article:489967 | pubmed:meshHeading | pubmed-meshheading:489967-O... | lld:pubmed |
| pubmed-article:489967 | pubmed:meshHeading | pubmed-meshheading:489967-A... | lld:pubmed |
| pubmed-article:489967 | pubmed:meshHeading | pubmed-meshheading:489967-R... | lld:pubmed |
| pubmed-article:489967 | pubmed:meshHeading | pubmed-meshheading:489967-F... | lld:pubmed |
| pubmed-article:489967 | pubmed:meshHeading | pubmed-meshheading:489967-M... | lld:pubmed |
| pubmed-article:489967 | pubmed:meshHeading | pubmed-meshheading:489967-C... | lld:pubmed |
| pubmed-article:489967 | pubmed:meshHeading | pubmed-meshheading:489967-P... | lld:pubmed |
| pubmed-article:489967 | pubmed:meshHeading | pubmed-meshheading:489967-A... | lld:pubmed |
| pubmed-article:489967 | pubmed:meshHeading | pubmed-meshheading:489967-M... | lld:pubmed |
| pubmed-article:489967 | pubmed:meshHeading | pubmed-meshheading:489967-D... | lld:pubmed |
| pubmed-article:489967 | pubmed:meshHeading | pubmed-meshheading:489967-A... | lld:pubmed |
| pubmed-article:489967 | pubmed:year | 1979 | lld:pubmed |
| pubmed-article:489967 | pubmed:articleTitle | Immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and specific heteroantiserum. I. Activation of peritoneal cells to mediate antibody-dependent cytotoxicity. | lld:pubmed |
| pubmed-article:489967 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:489967 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:489967 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:489967 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:489967 | lld:pubmed |
